Immunovant
IMVT
228 hedge funds and large institutions have $2.9B invested in Immunovant in 2023 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 67 increasing their positions, 73 reducing their positions, and 24 closing their positions.
200% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 24
42% more call options, than puts
Call options by funds: $70.2M | Put options by funds: $49.3M
26% more funds holding
Funds holding: 181 → 228 (+47)
13% more capital invested
Capital invested by funds: $2.57B → $2.9B (+$336M)
8% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 73
3.54% less ownership
Funds ownership: 51.19% → 47.65% (-3.5%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$98.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$33M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.1M |
| 4 |
Morgan Stanley
New York
|
+$26.6M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$69.8M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$66.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$54.7M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$34.2M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$28.8M |
IMVT Hedge Fund Activity: Q4 2023 in Review
228 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2023, worth a combined $2.9B — up 13% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new IMVT positions and 24 closed out — a net gain of 48 holders — while 67 added to existing stakes and 73 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $98.1M. The largest seller was Darwin Global Management, exiting entirely with an estimated $69.8M sold.
- 228 institutional investors held Immunovant (IMVT) as of Q4 2023, up from 181 in Q3 2023.
- Funds reported $2.9B of Immunovant stock for Q4 2023, up 13% quarter-over-quarter.
- 72 funds opened new Immunovant positions in Q4 2023 and 24 closed out, a net change of +48 holders.
- The largest Immunovant buyer in Q4 2023 was Point72 Asset Management, an estimated $98.1M added.
- The largest Immunovant seller in Q4 2023 was Darwin Global Management, an estimated $69.8M sold.
Based on aggregated 13F filings for Q4 2023.